A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms

被引:9
作者
Liu, Bo [1 ]
Kudo, Atsushi [1 ]
Kinowaki, Yuko [2 ]
Ogura, Toshiro [1 ]
Ogawa, Kosuke [1 ]
Ono, Hiroaki [1 ]
Mitsunori, Yusuke [1 ]
Ban, Daisuke [1 ]
Tanaka, Shinji [3 ]
Akashi, Takumi [2 ]
Tanabe, Minoru [1 ]
机构
[1] Tokyo Med & Dent Univ, Grad Sch Med, Dept Hepatobiliary & Pancreat Surg, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan
[2] Tokyo Med & Dent Univ, Grad Sch Med, Dept Human Pathol, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Oncol, Tokyo, Japan
关键词
Pancreatic neuroendocrine neoplasms; CD56; NCAM; Simple index; CONSENSUS GUIDELINES; ENDOCRINE NEOPLASMS; TUMORS; SURVIVAL; MANAGEMENT; GRADE; CELL; EPIDEMIOLOGY; EXPRESSION; SURGERY;
D O I
10.1007/s00535-019-01570-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The prognostic importance of the neuroendocrine (NE) markers involving neural cell adhesion molecule (NCAM) has been unclear enough to be adopted for WHO classification in patients with pancreatic neuroendocrine neoplasms (Pan-NENs). This study aimed to elucidate whether the three NE markers such as chromogranin A, synaptophysin, and NCAM decide prognoses for patients with well-differentiated tumors. Methods Between April 2002 and October 2018, 217 patients were included in this study. Tissue samples from tumors of Pan-NENs were immunochemically stained for the aforementioned NE markers. Diffuse and intense staining was defined as positive, while faint or focal staining and non-staining were considered negative. Results The median age of patients was 55 years. The median observation period was 1415 days. In multivariate analysis of progression-free survival (PFS), liver metastasis, Ki-67 index, and triple-positive staining of NE markers were risk factors. The 5-year PFS rate of patients with and without triple-positive NE markers was 56.3% and 23.8%, respectively (P < 0.0001). In multivariate analysis of overall survival (OS), R0 resection, Ki-67 index and triple-positive NE markers (hazard ratio 0.4, P = 0.02) were the risk factors. The 5-year OS rate of patients with and without triple-positive NE markers was 88.8% and 66.4%, respectively (P = 0.014). The tumors of patients without triple-positive NE markers were associated with large tumor size, a high mitotic rate and high Ki-67 index. Conclusions Triple-positive NE marker staining was a simple and practical indicator of prognoses in patients with well-differentiated Pan-NETs.
引用
收藏
页码:819 / 828
页数:10
相关论文
共 30 条
[1]   The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms [J].
Basturk, Olca ;
Yang, Zhaohai ;
Tang, Laura H. ;
Hruban, Ralph H. ;
Adsay, Volkan ;
McCall, Chad M. ;
Krasinskas, Alyssa M. ;
Jang, Kee-Taek ;
Frankel, Wendy L. ;
Balci, Serdar ;
Sigel, Carlie ;
Klimstra, David S. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (05) :683-690
[2]   Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors - Analysis of 3851 patients [J].
Bilimoria, Karl Y. ;
Talamonti, Mark S. ;
Tomlinson, James S. ;
Stewart, Andrew K. ;
Winchester, David P. ;
Ko, Clifford Y. ;
Bentrem, David J. .
ANNALS OF SURGERY, 2008, 247 (03) :490-500
[3]   Predictors of Survival After Operation Among Patients With Large Cell Neuroendocrine Carcinoma of the Lung [J].
Eichhorn, Florian ;
Dienemann, Hendrik ;
Muley, Thomas ;
Warth, Arne ;
Hoffmann, Hans .
ANNALS OF THORACIC SURGERY, 2015, 99 (03) :983-990
[4]   ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors [J].
Falconi, M. ;
Eriksson, B. ;
Kaltsas, G. ;
Bartsch, D. K. ;
Capdevila, J. ;
Caplin, M. ;
Kos-Kudla, B. ;
Kwekkeboom, D. ;
Rindi, G. ;
Kloeppel, G. ;
Reed, N. ;
Kianmanesh, R. ;
Jensen, R. T. .
NEUROENDOCRINOLOGY, 2016, 103 (02) :153-171
[5]   CD56 expression of neuroendocrine neoplasms on immunophenotyping by flow cytometry - A novel diagnostic approach to fine-needle aspiration biopsy [J].
Farinola, MA ;
Weir, EG ;
Ali, SZ .
CANCER CYTOPATHOLOGY, 2003, 99 (04) :240-246
[6]   Determining prognosis in patients with pancreatic endocrine neoplasms: Can the WHO classification system be simplified? [J].
Ferrone, Cristina R. ;
Tang, Laura H. ;
Tomlinson, James ;
Gonen, Mithat ;
Hochwald, Steven N. ;
Brennan, Murray F. ;
Klimstra, David S. ;
Allen, Peter J. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) :5609-5615
[7]   Differences in survival by histologic type of pancreatic cancer [J].
Fesinmeyer, MD ;
Austin, MA ;
Li, CI ;
De Roos, AJ ;
Bowen, DJ .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (07) :1766-1773
[8]   Recommendations for management of patients with neuroendocrine liver metastases [J].
Frilling, Andrea ;
Modlin, Irvin M. ;
Kidd, Mark ;
Russell, Christopher ;
Breitenstein, Stefan ;
Salem, Riad ;
Kwekkeboom, Dik ;
Lau, Wan-Yee ;
Klersy, Catherine ;
Vilgrain, Valerie ;
Davidson, Brian ;
Siegler, Mark ;
Caplin, Martyn ;
Solcia, Enrico ;
Schilsky, Richard .
LANCET ONCOLOGY, 2014, 15 (01) :E8-E21
[9]  
GARINCHESA P, 1991, AM J PATHOL, V139, P275
[10]   Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67 [J].
Genc, C. G. ;
Falconi, M. ;
Partelli, S. ;
Muffatti, F. ;
van Eeden, S. ;
Doglioni, C. ;
Klumpen, H. J. ;
van Eijck, C. H. J. ;
van Dijkum, E. J. M. Nieveen .
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (08) :2467-2474